Kymera Therapeutics, Inc. $KYMR Shares Sold by Cinctive Capital Management LP

Key Points

• Cinctive Capital Management LP reduced its stake in Kymera Therapeutics by 34.8%, selling 12,543 shares and holding a total of 23,492 shares valued at $643,000.
• Various institutional investors have altered their positions, with Advisors Asset Management Inc. increasing their stake by 81.7% to 4,959 shares and Yiheng Capital Management acquiring a new position worth $3,356,000.
• Kymera Therapeutics reported a loss of ($0.95) earnings per share for the last quarter, missing estimates, and noted a 55.1% decline in quarterly revenue year-over-year to $11.48 million.

Cinctive Capital Management LP decreased its stake in Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) by 34.8% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 23,492 shares of the company's stock after selling 12,543 shares during the period. Cinctive Capital Management LP's holdings in Kymera Therapeutics were worth $643,000 as of its most recent SEC filing.

Other large investors have also modified their holdings of the company. Wellington Management Group LLP lifted its position in Kymera Therapeutics by 13.0% during the 1st quarter. Wellington Management Group LLP now owns 5,996,873 shares of the company's stock worth $164,134,000 after acquiring an additional 689,547 shares in the last quarter. Janus Henderson Group PLC raised its stake in shares of Kymera Therapeutics by 2,397.9% during the fourth quarter. Janus Henderson Group PLC now owns 377,384 shares of the company's stock valued at $15,197,000 after purchasing an additional 362,276 shares during the period. Vanguard Group Inc. lifted its position in shares of Kymera Therapeutics by 7.0% during the first quarter. Vanguard Group Inc. now owns 5,231,392 shares of the company's stock worth $143,183,000 after purchasing an additional 344,080 shares in the last quarter. Siren L.L.C. boosted its stake in shares of Kymera Therapeutics by 9.1% in the first quarter. Siren L.L.C. now owns 3,240,313 shares of the company's stock valued at $88,687,000 after purchasing an additional 270,580 shares during the period. Finally, Nuveen LLC purchased a new position in shares of Kymera Therapeutics in the first quarter valued at $3,920,000.

Analysts Set New Price Targets

KYMR has been the topic of several analyst reports. HC Wainwright reaffirmed a "buy" rating and set a $60.00 price target (up previously from $54.00) on shares of Kymera Therapeutics in a research note on Thursday, June 26th. The Goldman Sachs Group raised Kymera Therapeutics to a "strong-buy" rating in a research report on Tuesday, July 15th. BTIG Research reiterated a "buy" rating and issued a $59.00 price target on shares of Kymera Therapeutics in a research note on Thursday, June 26th. Wall Street Zen downgraded Kymera Therapeutics from a "hold" rating to a "sell" rating in a report on Saturday, August 16th. Finally, Jefferies Financial Group set a $64.00 price objective on Kymera Therapeutics and gave the stock a "buy" rating in a report on Wednesday, June 25th. Two analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and one has issued a Hold rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of "Buy" and an average price target of $58.76.

Kymera Therapeutics Stock Performance

Shares of Kymera Therapeutics stock traded up $0.22 during trading on Tuesday, hitting $43.48. 493,702 shares of the stock were exchanged, compared to its average volume of 737,814. Kymera Therapeutics, Inc. has a 12 month low of $19.44 and a 12 month high of $53.27. The stock's fifty day moving average is $43.37 and its 200 day moving average is $37.03. The stock has a market cap of $3.11 billion, a PE ratio of -12.53 and a beta of 2.17.

Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last posted its earnings results on Monday, August 11th. The company reported ($0.95) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.83) by ($0.12). Kymera Therapeutics had a negative net margin of 616.03% and a negative return on equity of 31.60%. The firm had revenue of $11.48 million for the quarter, compared to analyst estimates of $17.37 million. During the same period in the previous year, the firm earned ($0.58) earnings per share. The company's revenue for the quarter was down 55.1% on a year-over-year basis. Sell-side analysts anticipate that Kymera Therapeutics, Inc. will post -2.79 EPS for the current fiscal year.

Insider Activity at Kymera Therapeutics

In other Kymera Therapeutics news, Director Bvf Partners L. P/Il bought 317,167 shares of the business's stock in a transaction on Monday, June 30th. The shares were purchased at an average price of $44.00 per share, with a total value of $13,955,348.00. Following the purchase, the director directly owned 2,798,795 shares of the company's stock, valued at approximately $123,146,980. The trade was a 12.78% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Bros. Advisors Lp Baker purchased 655,500 shares of the firm's stock in a transaction dated Monday, June 30th. The stock was acquired at an average cost of $44.00 per share, with a total value of $28,842,000.00. Following the purchase, the director owned 6,117,295 shares of the company's stock, valued at approximately $269,160,980. This represents a 12.00% increase in their position. The disclosure for this purchase can be found here. 16.01% of the stock is owned by company insiders.

About Kymera Therapeutics

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.